14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
BHVN vs TVTX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Travere Therapeutics, Inc. (TVTX) is the stronger overall head-to-head candidate over Biohaven Ltd. (BHVN) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). BHVN carries a Unified Composite Score of 42.1/100 (HOLD) at $13.90 (N/M Forward P/E, 0.0% operating margin), whereas TVTX carries 60.2/100 (BUY) at $49.90 (9.3x Forward P/E, -3.1% operating margin).
Technical & Structure Timing Caution: BHVN is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.4); meanwhile TVTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BHVN vs TVTX. Trailing 12-month operating profitability (BHVN 0.0% vs TVTX -3.1%) and valuation multiples (BHVN N/M vs TVTX 9.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $4.9B market capitalization and -3.1% operating margin.
OpEx & R&D Reinvestment64.2% of Rev ($418M)
90D Engineering Disclosures0 Published
Investor FAQ BHVN vs TVTX Key Questions & Quantitative Answers
As of Nov 16, 2026, Travere Therapeutics, Inc. (TVTX) is the stronger overall head-to-head candidate over Biohaven Ltd. (BHVN) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). BHVN carries a Unified Composite Score of 42.1/100 (HOLD) at $13.90 (N/M Forward P/E, 0.0% operating margin), whereas TVTX carries 60.2/100 (BUY) at $49.90 (9.3x Forward P/E, -3.1% operating margin). Technical & Structure Timing Caution: BHVN is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.4); meanwhile TVTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
TVTX leads the Growth & Scale pillar: BHVN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with TVTX at +36.2% YoY revenue growth and +0.0% YoY earnings growth on $651M TTM revenue (61.1% gross margin, -3.1% operating margin). On trailing 12-month operating scale, BHVN generates N/A in USD-normalized revenue versus $651M for TVTX. In operating R&D and SG&A reinvestment, BHVN deploys N/A (0 90-day corporate R&D disclosures) versus 64.2% of Rev ($418M) (0 disclosures) for TVTX.
TVTX screens cheaper on headline valuation multiples. BHVN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas TVTX trades at 9.3x Forward P/E, 25.8x Trailing P/E, N/M PEG, and 8.4x EV/Revenue (-4.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BHVN (-799.5% ROE) versus TVTX (-321.2% ROE) capital efficiency.
In options market volatility and institutional positioning, BHVN carries 91.5% implied volatility (18th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.41β · 111% Vol realized risk). By comparison, TVTX carries 39.1% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.39β · 44% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.